TG Therapeutics, Inc. (TGTX) Risk Assessment & Volatility Analysis

Comprehensive risk assessment and volatility analysis for TGTX including beta analysis, market risk, financial risk, and investment risk evaluation. Understand the potential risks and rewards of investing in TGTX stock with expert risk management insights.

Risk Assessment Summary

High market volatility (Beta > 1.5)

High short interest

High price volatility

Low governance risk

Governance Risk

Overall Risk Score

10/100Low

Audit Risk

9/100Low

Board Risk

10/100Low

Compensation Risk

10/100Low

Shareholder Rights Risk

3/100Low

Market Risk

Beta (5Y Monthly)

2.01Very High

52-Week Change

-4.79%Low

S&P 500 52-Week Change

12.66%Very High

Short Interest Ratio

12.74Very High

Short % of Float

20.78%Very High

Volatility (Annualized)

52.48%Very High

Financial Risk

Total Debt

$254.54M

Enterprise Value

$4.99B

Profit Margins

84.13%Low

Earnings Growth (QoQ)

9974.60%Low

Net Income to Common

$447.47M

Book Value

$4.26

Risk vs Reward Analysis

Risk Factors

Beta: 2.01

Volatility: 52.48%

Short Interest: 12.74

Potential Rewards

52-Week Change: -4.79%

Earnings Growth: 9974.60%

Profit Margin: 84.13%